SAB Biotherapeutics is trading at $2.83, down 5.03%; no confirmed company-specific announcement explains the October 12 decline. - The latest identified company news was an October 1 announcement of SAB-142 presentations at the October 9–11 Breakthrough T1D Congress; that prior event does not establish a cause. - Major indexes were mixed, with the Nasdaq down 0.50%; the broad-market move does not clearly explain the decline, and no specific catalyst was identified.